{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-086959","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.326866+00:00","generated_at":"2026-06-08T03:30:16.889076+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Silo Pharma amends U. Maryland license, sets new development milestones through 2033","bullets":["Third Amendment to Master License Agreement replaces entire diligence milestone schedule (Schedule C).","Key new milestones: complete in vitro peptide binding study by March 30, 2024; preclinical safety/efficacy by Sept 30, 2024.","GMP production and animal testing deadline: Feb 12, 2026; IND filing by Feb 12, 2027; Phase 1 first dosing by Feb 12, 2028.","Phase 2 first dosing by Feb 12, 2029; NDA filing by Feb 12, 2032; first commercial sale by Feb 12, 2033.","Royalty and other payment obligations under original MLA remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-086959","json":"https://secwatch.observer/filing/0001213900-23-086959.json","markdown":"https://secwatch.observer/filing/0001213900-23-086959.md","text":"https://secwatch.observer/filing/0001213900-23-086959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023086959/0001213900-23-086959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023086959/ea188215-8k_silo.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:30:16.889076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1c5d6bbf0fd1ad2576dc0f66884c37c369d93e6","claim":"Silo Pharma, Inc. amended Third Amendment to Master License Agreement with University of Maryland, Baltimore valued at amended and restated schedule of diligence milestones (effective 2023-11-10).","evidence_excerpt":"On November 10, 2023, our wholly-owned subsidiary Silo Pharma, Inc., a Florida corporation entered into a Third Amendment to Master License Agreement (the “Third Amendment”) with the University of Maryland, Baltimore, pursuant to which the parties agreed to an amended and restated schedule of diligence milestones for the Master License Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023086959/0001213900-23-086959-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"University of Maryland, Baltimore"},{"label":"Value","value":"amended and restated schedule of diligence milestones"},{"label":"Effective","value":"2023-11-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}